BioSpace News Archive

Every three minutes around the world, a child is diagnosed with cancer. In the United States, cancer remains the leading cause of death by disease for children, with brain tumors being the deadliest. Despite these statistics, a new drug has never been developed and approved specifically for pediatric brain cancer.

The Tauri-Gum™ Product Line Now Consists of 7 SKUs: Pomegranate (CBD), Blood Orange (CBD), Peach-Lemon (CBG), Pear Bellini (Vitamin C & Zinc), Mint (CBD), Black Currant (CBG), Cherry Lime Rickey (Caffeine)

Aspen Neuroscience, a private biotechnology company developing the first autologous neuron replacement therapy to treat Parkinson’s disease, announced today that it has appointed biotech leader Damien McDevitt, PhD, as President and Chief Executive Officer.

AbbVie (NYSE: ABBV), today announced that the European Commission (EC) has approved RINVOQTM (upadacitinib, 15 mg), an oral, once daily selective and reversible JAK inhibitor for the treatment of active psoriatic arthritis (PsA) in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate

ALSAC, the fundraising and awareness organization for St. Jude Children’s Research Hospital®, announced several new hires to its senior leadership team, effective immediately.

Vivera Pharmaceuticals, in partnership with Burkhan Group, is excited to announce a new testing initiative in Southern California.

Applied UV, Inc. (NasdaqCM:AUVI) (“Applied UV” or the “Company”), an infection control technology company that applies the power of narrow-range ultraviolet light (“UVC”) to destroy pathogens safely, thoroughly, and automatically, announced that the European Union Patent Office has notified the Company that a patent has been allowed for the invention of its core pathogen destroying device

NANOSCOPE THERAPEUTICS Inc., a clinical-stage biotechnology company determined to change lives through the ocular gene therapy, today announced that it has received an Orphan drug designation from FDA for gene therapy-based treatment of Stargardt disease, a form of inherited retinal degenerative disease caused by gene mutation and passed on to children.

ChoiceSpine LLC, a privately held spinal device manufacturer based in Knoxville, TN, announced today that the Food and Drug Administration (FDA) has provided additional 510(k) clearance to the Tiger Shark Cervical Spacer System.

The study conducted by a group of researchers at the James B. Edwards College of Dental Medicine at the Medical University of South Carolina showed that the Aegis VacStation, a chair-side extra-oral suction device from the CAO Group Inc., can effectively eliminate 100% of spatter and 99.8% of aerosol generated by high-speed dental procedures.